Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Credit Suisse initiates coverage of large-cap pharma stocks - Merck started at outperform

Stock Markets Nov 18, 2022 12:40
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters
 
MRK
-0.50%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABBV
+0.25%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LLY
+2.53%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
-0.56%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BMY
+2.31%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
-0.63%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Sam Boughedda

Credit Suisse analysts said Friday that the firm is initiating coverage of U.S. large-cap pharmaceuticals with four Outperform ratings, two Neutral ratings, and one Underperform rating.

The analysts started Merck & Company Inc (NYSE:MRK), AbbVie (NYSE:ABBV), Pfizer (NYSE:PFE), and Eli Lilly (NYSE:LLY) at Outperform, with Johnson & Johnson (NYSE:JNJ) and Bristol-Myers Squibb (NYSE:BMY) at Neutral and Amgen (NASDAQ:AMGN) at Underperform.

"With the macro backdrop uncertainty unlikely to resolve over the next few months, we see Large-Cap BioPharma as a key sector to own for defensive exposure at a reasonable price," wrote the analysts. "History shows U.S. Large-Cap Pharma outperforming in periods of macro volatility, and we currently favor U.S. Pharma over Europe given recent liability litigation risks. Despite Pharma's unchanged long- term secular growth drivers and high margins to absorb cost inflation, U.S. Pharma's one-year forward P/E is significantly below other U.S. defensive sectors (U.S. Pharma P/E is 16-17x vs. 18-20x for utilities and consumer staples) despite having higher 2021-25E revenue growth (7% vs. 4-5%, respectively)."

The analysts added that the firm believes Pharma, unlike other defensive sectors can provide optionality outside of an economic cycle through its product-driven catalysts, and they continue to see less focus on valuation in decision-making given a continued volatile macro backdrop, with high growth and solid fundamentals preferred.

"While overhangs remain, we think that drug pricing concerns following the U.S. Inflation Reduction Act of 2022 are manageable and that the 2025-plus patent cliff is well understood. In the current climate, we prefer names with higher short- to mid-term growth and companies that can affect meaningful change through pipeline success, product execution, and impactful M&A," the analysts added.

Credit Suisse initiates coverage of large-cap pharma stocks - Merck started at outperform
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email